STXS dividend history

ST. LOUIS, May 10, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the first quarter ended March 31, 2021. "The highlight of the first quarter is Stereotaxis' return to robust double digit revenue growth with 50% topline growth," said David Fischel, Chairman and CEO. "The results reflect the initial impact of the first wave of our strategic innovation plan." "During the quarter two robotic systems were shipped to hospitals establishing new robotic electrophysiology practices, triggering partial revenue recognition of those systems. Since the quarterly resu

ST. LOUIS, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the fourth quarter and full year ended December 31, 2020. “2020 was a year of significant progress despite a challenging macro environment,” said David Fischel, Chairman and CEO. “The highlight of the year was receipt of FDA clearance for the Genesis RMN System and successful installations of the first systems in the United States and Europe. We begin 2021 with purchase orders for five robotic systems reflecting the initial green shoots of a broad-based global resurgence in interest in our